semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Celiac Disease adult patients, both genders, aged between 18-70 years; 2. with suspected CD (i.e. affected with one or more of the following symptoms: chronic diarrhea or constipation, alternating bowel habits, abdominal pain, dyspepsia, recurrent aphthosis, dental enamel defects, thyroiditis, dermatitis, osteoporosis, joints pain, weight loss, anemia, cryptogenetic hypertransaminasemia); 3. with weakly positive [e.g. 2-3xN] serum anti-tTG antibodies; and d) subjects with a family history of CD  patients with IgA deficiency, type 1 diabetes, inflammatory bowel diseases (Crohn's disease or ulcerative colitis), Helicobacter pylori infection and other gastrointestinal infection, and pregnancy
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Healthy age ≥ 18 and ≤55 years BMI ≥ 18.5 and ≤ 29.9 kg/m2 healthy male subjects as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead ECG at the screening visit signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation non-smoker (a subject is considered to be a non-smoker if he has never smoked or has stopped smoking ≥ 6 months before the screening visit) agree not to take any prescription medications or non-prescription drugs (including herbal preparations and vitamins) without approval by the investigator and not to receive vaccinations during the course of the study agree not to eat oranges, grapefruits, broccoli, Brussels sprouts, or char grilled meats and not to drink grapefruit juice during the course of the study agree not to drink alcoholic beverages during the course of the study agree not to drink or eat caffeine and theobromine containing beverages and foods during the course of the study  any finding of the medical examination (including Blood Pressure, Pulse Rate, and ECG) deviating from normal and of clinical relevance gastrointestinal, hepatic, renal, respiratory (e.g. asthma), cardiovascular, metabolic, immunologic, haematological, oncological, or hormonal disorders any surgical or medical condition that could interfere with the administration of the study drug or interpretation of the study results diseases of the Central nervous system (CNS) (such as epilepsy) or psychiatric disorders or neurological disorders relevant history of orthostatic hypotension, fainting spells, or blackouts chronic or relevant acute infections history of allergy/hypersensitivity (including drug allergy) considered relevant to the trial as judged by the investigator immunisation during the 2 weeks prior to the screening visit known intolerance to benzodiazepines known intolerance to the active and/or inactive ingredients in caffeine, warfarin, vitamin K1, omeprazole, or dextromethorphan
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Child Malnutrition Child Overnutrition Malnutrition in Children Malnutrition, Child Nutrition Disorders, Child Malnutrition Age 18 to 60 years Premenopausal BMI < 45 during enrollment Apparently healthy With a child in her care between the ages of 5 and 13 years  Pregnant or breastfeeding With a hysterectomy in the past 3 months Alcohol consumption > 14 drinks a week Use of vitamin supplements
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.083-999.0,  Pulmonary Arterial Hypertension of Congenital Heart Disease The patient has a congenital heart disease other than patent foramen ovale The diagnosis of pulmonary hypertension was confirmed by cardiac catheterization. Only patients with Eisenmenger syndrome can be included without catheterization The catheterization was done after 1 January 2009 A mean pulmonary artery pressure > 25 mm Hg Pulmonary vascular resistances > 3 piece Wood m2 Pulmonary capillary pressure available Consent for in the study must be signed by parents or legal guardians for minors, by the patient for adults The patient he had a surgical procedure or interventional catheterization cardiac catheterization between his diagnosis and in the observatory? If yes, it can only be included if a new catheterization confirmed the persistence of HTAP at least 6 months after the procedure Patient follow-up (at least once a year) in the center for its HTAP associated with congenital heart disease its
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 21.0-55.0,  Healthy All participants in the study should be healthy males and females. Volunteers will be 21 to 55 years of age have a Body Mass Index (BMI) of 19.9 to 29.9 kg/m2 and have a resting heart rate (HR) (after 10 min. in the supine position) of more than 55 beats per minute (bpm) Only post-menopausal females, or those who had had a hysterectomy, could participate. All females had to have a negative pregnancy test In accordance with good clinical practice (GCP) and the local legislation all volunteers had to give their written informed consent prior to admission to the study  Any finding of the medical examination (including BP, HR and ECG) deviating from normal and of clinical relevance Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Diseases of the central nervous system or psychiatric disorders or neurological disorders History of relevant orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the Investigator Intake of drugs with a long half-life (> 24 hours) within ten half-lives of the respective drug before enrolment in the study Use of any drugs which might influence the results of the trial within two weeks prior to administration or during the trial Participation in another trial with an investigational drug (≤ two months prior to administration or during the trial) Smoker (> 10 cigarettes or > 3 cigars of > 3 pipes/day)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Post Thrombotic Syndrome Chronic Thromboembolic Pulmonary Hypertension Venous Thrombosis Patients with objectively verified first time DVT diagnosed after 01.01.11 for study A, OR objectively verified DVT and/or PE dignosed after 01.04.14 for study B years of age Signed informed written consent  Patients who refuse to consent Patients who have been treated with other anticoagulants than thoose included in the study Patients who can not participate due to logistic reasons
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Sickle Cell Disease Sickle Cell Trait Age 18-45 years Female Regular menstrual periods Self-identification of African American race  Taking oral contraceptives or medications known to influence bone metabolism (e.g. Glucocorticoids, anti-resorptive or anabolic medications for osteoporosis, pharmacologic Vit D dosing) Known metabolic bone disorder (e.g. uncontrolled thyroid disease, hyperparathyroidism) Pregnant, breast-feeding, or within 3 months post-partum Taking an investigational drug
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pain Male and female subjects >18 years old Complaining functional discomfort associated to joints and/or muscles disorders, motility disorders and/or initial SMFA score higher or equal to 15  Able to give a written or verbal informed consent Affiliated or beneficiary of social security  IMC>30kg/m Acute or chronic, progressive joint disorders (arthrosis, rheumatoid arthritis, acute articular rheumatism) of first or second degree and correlated treatments Subjects refusing of giving their written or verbal informed consent Subjects deprived of freedom following an administrative or judicial decision Participation to another clinical trial in the last four weeks People who already participated to another research that comprises an period still ongoing at the time of
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Pain Delayed Onset Muscle Soreness no clinically significant medical conditions BMI between 18-30 negative drug, alcohol, pregnancy screens other protocol-defined may apply  no upper extremity workout in last 6 months no job requiring heavy lifting history of muscle disorders allergy or intolerance to study drug history of recent pain medication use other protocol-defined
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Progression of Rheumatoid Arthritis Osteoarthritis of Multiple Joints RA and/or OA  N/A
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-49.0,  Polycystic Ovary Syndrome Hypovitaminosis D Female gender Aged between 18 and 49 years old Ethnic group (Caucasian, Middle-eastern) Overweight (BMI 25-30 kg^m2) Diagnosed with Polycystic ovary syndrome according to Rotterdam (Rotterdam SHRE-ASRM Sponsored Polycystic ovary syndrome consensus workshop group, 2004) Diagnosed with hypovitaminosis D (serum 25(OH)D level < 20 ng/mL) Inadequate dietary intake of vitamin D (<600 IU/day or <15μg/day) Physical examination being assessed and accepted by the attending physician Systolic blood pressure within the normal range (90-140 mmHg) Diastolic blood pressure within the normal range (60-90 mmHg)  Female participants who are pregnant, lactating or planning pregnancy during the course of the study Ethnic group: non Caucasian Females aged <18 or >49 years old Underweight, normal body weight ,Body Mass Index (BMI) < 25 kg^m2 Obese or morbidly obese (BMI > 30 kg/m2) Diagnosis with type 1 or type 2 diabetes mellitus, hypothyroidism, hyperthyroidism, liver disease, renal dysfunction, cardiovascular diseases, androgen-secreting tumor, Cushing syndrome, congenital adrenal hyperplasia, hyperprolactinemia, and/or virilism Known history or presence of food allergies or intolerance (e.g dairy products or gluten-containing foods), or any known condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs History of drug or alcohol abuse, smoking of 10 cigarettes or more (or equivalent) per day Participants who took medications known to affect metabolic parameters, such as metformin and corticosteroid drugs, vitamin D and calcium Adequate dietary intake of vitamin D (600 IU/day or 15μg/day or more)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Chronic Pain Chronic low back pain (predominantly below L5 vertebra) of moderate intensity (visual analog scale score more than 3) for greater than 3 months Patients with 3 or more positive provocative tests out of 6 (Annexure-1) Positive X-ray, MRI or nuclear scan findings Failure to achieve adequate improvement with comprehensive non-operative treatments, including but not limited to activity alteration, physiotherapy and/or psychological counselling  Systemic infection (H/O fever, chills and/or night sweats) or localized infection at anticipated introducer entry site Spinal pathology that may impede recovery such as spondylolisthesis at L5/S1, or scoliosis Symptomatic foraminal or central canal stenosis H/O potentially confounding intervertebral disc disease or zygapophyseal joint pain Pregnancy Active radicular pain Immunosuppressive conditions (H/O TB, AIDS, cancer, diabetes, surgery <3 months) Allergy to medications used in the procedure High narcotic use (>30 mg morphine daily or equivalent) Contraindications pertaining to the use of platelet concentrate like history of thrombocytopenia, use of anticoagulant therapy, active infection, tumor and metastatic disease
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sprain of Sacroiliac Ligament Low Back Pain Osteoarthritis Nos, of Sacroiliac Joint years of age or older Clinical presentation compatible with SI joint origin pain (back pain below L5; localized to the SI joint area; >2 positive of 5 SI joint provocative tests) >50% index pain relief with at least one SIJ intra-articular local anesthetic block and at least one SIJ lateral branch block using the conventional fluoroscopically guided lateral branch block technique. Pain diary records for these interventions need to be on file  Under 18 years of age Presence of clinical and investigative evidence of inflammatory spondyloarthropathy, fibromyalgia, radiculopathy, symptomatic spinal stenosis, facetogenic or discogenic low back pain, generalized infection, localized infection in the area of the low back/SIJs, coagulopathy or anticoagulation, allergy to local anesthetic
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 35.0-85.0,  Osteoarthritis, Knee Voluntary signature of the IRB approved Informed Consent 2. Unilateral osteoarthritic male or female ages 35-85 3. Pain, swelling, and/or functional disability in the affected knee consistent with osteoarthritis in one knee joint 4. Physical examination consistent with osteoarthritis in one knee joint 5. Restricted range of motion of the affected knee (<135 degrees in flexion and/or >0 degrees of extension) 6. Kellgren-Lawrence grade 2 or greater knee osteoarthritis with diagnostic MR imaging of the affected knee showing osteoarthritis 7. Limited knee effusion in osteoarthritic knee (i.e. not more than 20 ml of visible joint fluid on ultrasound examination of the knee.) 8. Normal range of motion of the unaffected knee 9. No sign of pain, swelling, and/or functional disability of the unaffected knee 10. No history of acute injury in the unaffected knee 11. Is independent, ambulatory, and can comply with all post-operative evaluations and visits  Knee injections of any type within 6 months prior to the study. 2. Inflammatory or auto-immune based joint diseases or other lower extremity pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout) 3. Quinolone or Statin induced myopathy/tendinopathy 4. Symptomatic lumbar spine pathology (e.g. radicular pain) 5. Severe neurogenic inflammation of the cutaneous nerves about the knee or thigh (i.e. evidence of complex regional pain syndrome or central sensitization with allodynia present on exam). 6. Contraindications for MRI 7. Tested positive or has been treated for a malignancy in the past five years or is suspected of having a malignancy or is currently undergoing radiation or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed injection site 8. Condition represents a worker's compensation case 9. Currently involved in a health-related litigation procedure 10. Is pregnant 11. Bleeding disorders 12. Currently taking anticoagulant or immunosuppressive medication 13. Allergy or intolerance to study medication 14. Use of chronic opioid 15. Documented history of drug abuse within six months of treatment 18) Any other condition, that in the opinion of the investigator, that would preclude the patient from enrollment
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Healthy All subjects must comply with all the following Having respected dietary restrictions 2 days before the visit Having obtained his/her or his/her legal representative's informed consent  Subjects representing one or more of the following are excluded from participation in the study Pregnancy as per precaution principal to avoid risks linked to X-ray exposure Any pathology (infectious or other) having required an antibiotic therapy within 1 month prior to the beginning of the study Any therapy (contraception apart) within the 2 days before the visit day Subject who cannot be expected to comply with measures Currently participating or having participated in another clinical trial during the last 3 months prior to the beginning of this study
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hemophilia A Hemophilia B Key Have a medically documented diagnosis of hemophilia A or B that is being treated prophylactically with a factor replacement product not designed to have a prolonged half-life and satisfy a therapeutic indication for rFVIIIFc/rFIXFc per the approved local label Have at least 50 prior exposure days (EDs) to any combination of factor replacement products Have documented pre-study data available that confirm fulfillment of the Have no measurable inhibitor activity in a sample obtained within 4 weeks prior to the Baseline visit, and absence of clinical signs or symptoms of decreased response to the current factor replacement product Key  Have a diagnosis of any bleeding disorder other than hemophilia A or hemophilia B or an additional coagulation disorder(s) in addition to hemophilia A or hemophilia B Have a prior history of anaphylaxis associated with any factor VIII (FVIII)/ factor IX (FIX) or intravenous immunoglobin administration Had an inhibitor within 5 years before the Baseline visit. Note: A family history of inhibitors will not the patient Past or current treatment with any factor replacement product with a prolonged half-life, including an Fc product, for the treatment of hemophilia NOTE: Other Protocol Defined Inclusion/ May Apply